Antibiotic resistance has become one of the most urgent health challenges of our time, contributing to millions of deaths every year. Two main factors drive this crisis: first, there’s been little innovation in antibiotic development over the past few decades, and second, bacteria have evolved to resist the drugs we do have. As a result, many infections are becoming harder, and sometimes impossible, to treat. But rather than focusing solely on killing bacteria, researchers are exploring a different strategy—one that targets how bacteria cause disease without necessarily wiping them out.
A recent study shines a light on this alternative approach, known as antivirulence therapy. Instead of killing bacteria, antivirulence drugs aim to stop bacteria from causing harm by disrupting their ability to invade or damage human cells. This approach could help slow down the rise of resistance, as bacteria face less pressure to evolve defenses against these drugs. And in a twist that’s catching the attention of scientists, researchers are turning to an unlikely source for these antivirulence compounds: marine microbes.
Traditional antibiotics work by killing bacteria or stopping them from growing. While effective, this often leads to bacteria developing resistance over time. Antivirulence therapies, on the other hand, don’t kill bacteria. Instead, they block the mechanisms that make them dangerous. The idea is that by targeting specific bacterial processes—like the production of toxins or the ability to latch onto host cells—scientists can make the bacteria harmless without contributing to the growing problem of resistance.
This study focused on Enteropathogenic Escherichia coli (EPEC), a type of bacteria responsible for severe diarrheal diseases, particularly in young children. EPEC’s ability to cause disease depends on its ability to attach to the intestinal lining and create lesions that disrupt normal function. One key protein, called Tir, plays a central role in this process, helping the bacteria form harmful “pedestals” that damage the intestinal cells. By preventing Tir from doing its job, antivirulence compounds could stop EPEC from causing illness without killing it outright.
The researchers behind this study explored an unusual and largely overlooked source for antivirulence compounds: marine actinobacteria, microbes found in ocean environments, including the deep sea and ocean floor. While soil bacteria have long been a focus of antibiotic discovery, marine microbes have received far less attention. Yet, they could offer a treasure trove of new compounds with medicinal potential.
In this case, scientists collected marine actinobacteria from the Arctic waters near Svalbard, a remote region known for its cold, pristine environment. After growing these bacteria in the lab, they extracted and tested the compounds the microbes produced to see if any could block EPEC’s ability to cause disease. Specifically, they looked for compounds that could interfere with Tir translocation and pedestal formation—two critical steps in EPEC’s virulence process.
The study revealed that several extracts from the marine actinobacteria were effective in blocking EPEC’s virulence, suggesting that the ocean’s microbial life holds promise for developing new treatments that work differently from traditional antibiotics.